Select Medical Reports Q1 2025 Results: Revenue Up but Challenges in EBITDA and Liquidity Persist

Select Medical Holdings Corporation (NYSE: SEM) has reported its financial results for the three months ended March 31, 2025. The overall performance indicates areas of improvement, alongside some challenges in its operations.

Key Highlights:

• Revenue: $1.35 billion for Q1 2025, a 2.4% increase from $1.32 billion in Q1 2024.
• Income from Continuing Operations: $74.7 million in Q1 2025, compared to $61.5 million in Q1 2024.
• Net Income: $74.7 million attributed to common stockholders, down from $96.9 million, largely due to the spin-off of Concentra.
• Earnings Per Share (EPS): $0.44 per share for Q1 2025, compared to $0.33 in Q1 2024 for continuing operations.
• Adjusted EBITDA: $151.4 million with a margin of 11.2%, down from $165.8 million and a 12.5% margin in Q1 2024.

Positive Aspects:

• Revenue growth was driven by the rehabilitation hospital segment, which saw a 15.7% increase in revenue.
• Significant drop in interest expense to $29.1 million from $40.7 million, highlighting improved debt management.
• Decline in general and administrative expenses from 3.7% to 2.4% of total revenue, indicating better cost control.

Negative Aspects:

• The critical illness recovery hospital segment experienced a significant revenue drop of 2.9%, attributed to lower reimbursement rates from Medicare and reduced revenue per patient day.
• Adjusted EBITDA declined by 8.6% year-over-year, reflecting increased competitive pressure and operational challenges.
• Cash and cash equivalents decreased to $53.2 million from $92.6 million, indicating potential liquidity concerns.

Financial Statistics:

• Current Assets: $1.09 billion, up from $1.02 billion as of December 31, 2024.
• Total Assets: $5.70 billion, up from $5.61 billion at year-end.
• Current Liabilities: $944.8 million, a decrease from $977.6 million.
• Long-Term Debt: $1.77 billion, an increase from $1.69 billion.
• Repurchased 649,804 shares at an average price of $17.52 during Q1 2025.

Conclusion: While Select Medical Holdings Corporation shows strong revenue growth in key segments, challenges in maintaining EBITDA margins and liquidity management need attention in the coming quarters. The company's ability to navigate the regulatory landscape and economic pressures will be critical to sustaining its growth trajectory.